MicroRNAs as Biomarkers of B-cell Lymphoma

Solé, Carla; Arnaiz, Esther; Lawrie, Charles H.

doi:10.1177/1177271918806840

Cited by 29 publications

(27 citation statements)

References 177 publications

(231 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is consistent with other studies that reported changes in miRNA composition in tissues distinct from the primary location of clinical disease [16,[21][22][23]. Previous studies have investigated miRNA profiles in non-Hodgkin lymphoma, most often the diffuse large B cell lymphoma subtype (DLBCL) [11,14,24]. DLBCL is a relative infrequent subtype of NHOL [2], reflected by only two cases in our study.…”

Section: Discussionsupporting

confidence: 93%

“…DLBCL is a relative infrequent subtype of NHOL [2], reflected by only two cases in our study. In contrast, the most frequent NHOL subtype in our study was extranodal marginal zone lymohoma (EMZL), for which serum miRNAs studies are rare [11,24]. Nonetheless, studies of lymphoma biopsies have shown an increased expression of miR-223 and miR-193 in EMZL [25], and a downregulation of miR-29a, miR-223, and miR-140 in DLBCL [26].…”

Section: Discussionmentioning

confidence: 65%

“…MicroRNAs (miRNAs) are small non‐coding regulatory RNAs that are present in almost all biological tissues and regulate gene expression by interfering with RNA translation . Changes in the composition of miRNAs are associated with a plethora of human pathologies, including inflammation and cancer . Consequently, miRNAs are candidate biomarkers that may aid in diagnosis and prognostic studies .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A pan‐inflammatory microRNA‐cluster is associated with orbital non‐Hodgkin lymphoma and idiopathic orbital inflammation

et al. 2019

View full text Add to dashboard Cite

Non‐Hodgkin orbital lymphoma (NHOL) and idiopathic orbital inflammation (IOI) are common orbital conditions with largely unknown pathophysiology that can be difficult to diagnose. In this study we aim to identify serum miRNAs associated with NHOL and IOI. We performed OpenArray® miRNA profiling in 33 patients and controls. Differentially expressed miRNAs were technically validated across technology platforms and replicated in an additional cohort of 32 patients and controls. We identified and independently validated a serum miRNA profile of NHOL that was remarkably similar to IOI and characterized by an increased expression of a cluster of eight miRNAs. Pathway enrichment analysis indicated that the miRNA‐cluster is associated with immune‐mediated pathways, which we supported by demonstrating the elevated expression of this cluster in serum of patients with other inflammatory conditions. The cluster contained miR‐148a, a key driver of B‐cell tolerance, and miR‐365 that correlated with serum IgG and IgM concentrations. In addition, miR‐29a and miR‐223 were associated with blood lymphocyte and neutrophil populations, respectively. NHOL and IOI are characterized by an abnormal serum miRNA‐cluster associated with immune pathway activation and linked to B cell and neutrophil dysfunction.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 65%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A pan‐inflammatory microRNA‐cluster is associated with orbital non‐Hodgkin lymphoma and idiopathic orbital inflammation

et al. 2019

View full text Add to dashboard Cite

show abstract

“…group of neoplasms classified primarily by histopathology and is often challenging to accurately diagnose. 2,3 More than half of the patients with B-cell NHL can achieve long-term remission; strikingly, the overall cure rate for some subtypes in developed countries is approximately 90%, especially DLBCL. However, these therapies are sometimes ineffective, particularly for patients with high-risk disease or late-stage diagnosis, or the rare malignant lymphoma, MCL.…”

Section: Introductionmentioning

confidence: 99%

Retracted: Bevacizumab synergises with the BCL 2 inhibitor venetoclax to effectively treat B‐cell non‐Hodgkin's lymphoma

Wang

Peng

Sun

et al. 2019

European J of Haematology

View full text Add to dashboard Cite

Objectives:Our present study has shown a potential role for VEGF-A-mediated autocrine signalling to promote survival and proliferation of SU-DHL-6 cells, but the cells could not undergo apoptosis but rather decrease proliferation after bevacizumab treatment. Therefore, we would like to further study the antitumour efficacy of venetoclax (BCL2 inhibitor) in combination with bevacizumab in B-cell NHL. Methods:The human cytokine antibody array, RT-qPCR, Western blot, ELISA, apoptosis assay and xenografted mouse model et al were used.

show abstract

“…Many miRNAs have been identified as biomarkers of B-cell lymphoma. 22 , 23 Schneider et al. 17 revealed that miR-28 expression is downregulated in B-cell lymphomas, suggesting that silencing of miR-28 will contribute to lymphomagenesis.…”

Section: Discussionmentioning

confidence: 99%

MiR-28-5p mediates the anti-proliferative and pro-apoptotic effects of curcumin on human diffuse large B-cell lymphoma cells

et al. 2020

View full text Add to dashboard Cite

Objective To investigate the anti-proliferative and pro-apoptotic effects of curcumin on diffuse large B-cell lymphoma (DLBCL) cells and explore the mechanism. Methods OCI-LY7 cells were treated with curcumin (2.5, 5, 10, 20, and 40 μM) for 24, 48, or 72 hours. Cell viability and apoptosis were determined using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5 diphenyl tetrazolium bromide assay and TdT-mediated dUTP nick-end labeling staining, respectively. MiR-28-5p expression was detected via qRT-PCR. The binding site of miR-28-5p was predicted using online databases and verified using the dual-luciferase reporter assay. MiR-28-5p overexpression and inhibition were achieved via transfection with an miR-28-5p mimic and inhibitor, respectively. Results Curcumin decreased the viability of OCI-LY7 cells in a concentration- and time-dependent manner, and these effects were attenuated by miR-28-5p inhibition. MiR-28-5p expression was upregulated by curcumin. Curcumin increased the numbers of apoptotic cells and upregulated cleaved caspase-3 expression, and these effects were attenuated by miR-28-5p inhibition. The dual-luciferase reporter assay confirmed that miR-28-5p directly targets the 3′-untranslated region of BECN1. Curcumin downregulated BECN1 and microtubule-associated protein 1 light chain 3 beta-II/I expression and upregulated p62 expression. Conclusions Our results described the curcumin exerted anti-proliferative and pro-apoptotic effects on OCI-LY7 cells through a mechanism potentially involving miR-28-5p.

show abstract

MicroRNAs as Biomarkers of B-cell Lymphoma

Cited by 29 publications

References 177 publications

A pan‐inflammatory microRNA‐cluster is associated with orbital non‐Hodgkin lymphoma and idiopathic orbital inflammation

A pan‐inflammatory microRNA‐cluster is associated with orbital non‐Hodgkin lymphoma and idiopathic orbital inflammation

Retracted: Bevacizumab synergises with the BCL 2 inhibitor venetoclax to effectively treat B‐cell non‐Hodgkin's lymphoma

MiR-28-5p mediates the anti-proliferative and pro-apoptotic effects of curcumin on human diffuse large B-cell lymphoma cells

Contact Info

Product

Resources

About